Anti-Mouse CD8 [Clone YTS-169] — Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse CD8 [Clone YTS-169] — Purified in vivo PLATINUM™ Functional Grade
Product No.: C2850
Clone YTS-169 Target CD8 Formats AvailableView All Product Type Monoclonal Antibody Isotype Rat IgG2b κ Applications Depletion , FC , IHC FF , in vivo , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen CBA mouse thymocytes Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2829606 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this YTS-169 antibody for staining cells in flow cytometry is ≤ 0.2 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. WB The suggested concentration for this YTS-169 antibody for use in western blotting is 1-10 μg/ml. Additional Applications Reported In Literature ? IHC (Frozen) Depletion Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone YTS-169 recognizes mouse CD8. Background CD8 is made up of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8 is part of the Ig superfamily that expresses primarily as CD8a homodimers. CD8a is a 32-34 kD type I glycoprotein that can also form heterodimers with CD8b. CD8 is an antigen co-receptor on T cells that mediates efficient cell to cell interactions within the immune system. CD8 coupled with the T cell receptor on the T lymphocyte recognizes an antigen displayed by an antigen presenting cell (APC) in the context of class I MHC molecules. The CD8 co-receptor also plays a role in T cell signaling by interacting with Lck (lymphocyte-specific protein tyrosine kinase) which leads to the activation of transcription factors that affect the expression of certain genes.
Antigen Distribution CD8 is expressed on blood lymphocytes, a subset of NK cells, and thymocytes. Persons with HIV exhibit increased levels of CD8+ lymphocytes. Ligand/Receptor MHC class I molecule PubMed Research Area Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. The most common in vivo application of clone YTS-169 in mice is the selective depletion of CD8⁺ T cells, primarily cytotoxic T lymphocytes, to study immune responses or model immune modulation. Key in vivo uses include:
Additional applications sometimes reported (less common than depletion studies):
In summary, CD8⁺ T cell depletion is the principal in vivo application of clone YTS-169 in mouse models. This enables mechanistic studies of immune responses where the absence of cytotoxic T cells is informative. Commonly used antibodies or proteins paired with YTS-169 (anti-mouse CD8α) in the literature include anti-CD4 antibodies and other CD8 antibodies, especially for distinguishing T cell subsets or for conducting immune cell depletion experiments. Key details and common use cases:
Additional proteins/antibodies sometimes co-used:
Summary table:
In summary, anti-CD4 antibodies (often clone GK1.5) are the most common co-used reagent with YTS-169, with other anti-CD8 antibodies and recombinant proteins used for more specialized applications. Clone YTS-169 (also cited as YTS169.4) is a rat monoclonal antibody widely used in scientific literature for identifying, depleting, and analyzing mouse CD8+ T cells in vivo and in vitro. Its use is fundamental in immunology, particularly in studies probing T cell function, immune cell depletion, and the role of CD8+ T cells in disease models. Key findings from scientific literature citing clone YTS-169 include:
Summary of core uses of YTS-169 citations:
In summary, clone YTS-169 and YTS169.4 are fundamental in CD8+ T cell research, enabling cell depletion, detection, and immuno-functional studies in mice across diverse fields such as oncology, autoimmunity, and virology, with usage and limitations well documented in the literature. Dosing regimens for clone YTS-169 in mouse models demonstrate considerable variability based on experimental objectives, mouse strain characteristics, disease model complexity, and the desired extent and duration of CD8+ T cell depletion. Standard Dosing ParametersThe typical dosing protocol for clone YTS-169 involves administering 200–400 µg per mouse every 3–7 days through intraperitoneal (i.p.) or intravenous (i.v.) injection. This protocol closely mirrors established standards for other anti-CD8 clones like 2.43, which commonly use doses ranging from 100 µg to 500 µg per mouse. However, dosing for YTS-169 can extend from the low hundreds of micrograms up to 1 mg per mouse per dose depending on specific experimental requirements. Frequency and Administration RoutesThe dosing schedule typically follows a maintenance pattern where antibody is administered every 3 to 7 days to sustain effective CD8+ T cell depletion. Some protocols employ an initial higher loading dose followed by lower maintenance doses to balance depletion efficiency with safety considerations. The preferred routes of administration are intraperitoneal or intravenous injection, with each route potentially affecting the kinetics and efficiency of depletion. Model-Specific VariationsOne documented example demonstrates the flexibility of dosing schedules: in autoimmunity studies using sOVA/OT-I mice, researchers administered three doses of YTS169.4 on days 5, 7, and 9 after birth to delay disease onset. In tumor immunology studies, mice received 200 µg of anti-CD8α (clone YTS169.4) for investigating immune responses to tumor heterogeneity. Factors Influencing Dosing DecisionsSeveral critical factors determine the optimal dosing regimen for any particular experiment. Mouse strain characteristics affect antibody pharmacokinetics and immune responsiveness. The specific disease model being studied influences both the timing and magnitude of depletion required. Experimental goals—whether seeking transient depletion for mechanistic studies or sustained depletion for therapeutic modeling—fundamentally shape dosing strategies. Finally, the desired duration of CD8+ T cell absence must be balanced against potential immunogenicity from repeated antibody administration. The depleting activity of YTS 169.4 makes it highly effective for in vivo applications, but researchers must carefully titrate their specific protocols to achieve optimal results for their particular experimental context. References & Citations1. Parnes, J. R. et al. (1989) Adv. Immunol. 44:265 2. Reinherz, E. L. et al. (1980) J. Immunol. 124:1301 3. Fischer, A. et al. (1983) Immunology 48:177 4. Merkenschlanger, M. et al. (1988) Eur. J. Immunol. 18:1653 5. Leukocyte Typing: 3rd Workshop: Code No. 567; 4th Workshop: Code No. N31 Technical ProtocolsCertificate of Analysis |
Formats Available
